Dermata Therapeutics develops dermatologic and skincare products around its Bioneedle Delivery System, Spongilla technology and direct-to-consumer Tome brand. Company news commonly covers the shift from pharmaceutical development toward OTC skincare, development of a once-weekly acne treatment and skin refresh products, patent activity for acne, dermal filler and botulinum toxin applications, and financing or governance updates tied to its Nasdaq-listed common stock and warrants.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.96%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.96%
Tags
News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.4%
Tags
-
News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.06%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
106.25%
Tags
FAQ
What is the current stock price of Dermata Therapeutics Warrant (DRMAW)?
Dermata Therapeutics Warrant (DRMAW) last closed at $0.0006.